Bard Financial Services Inc. Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Bard Financial Services Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,390 shares of the company’s stock after selling 3,500 shares during the quarter. Novo Nordisk A/S accounts for approximately 0.9% of Bard Financial Services Inc.’s investment portfolio, making the stock its 28th largest position. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $7,345,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Rhumbline Advisers raised its position in Novo Nordisk A/S by 0.4% in the 2nd quarter. Rhumbline Advisers now owns 60,974 shares of the company’s stock worth $8,703,000 after purchasing an additional 270 shares during the period. Savant Capital LLC grew its position in Novo Nordisk A/S by 16.2% in the 2nd quarter. Savant Capital LLC now owns 12,587 shares of the company’s stock valued at $1,797,000 after acquiring an additional 1,751 shares during the last quarter. Hanlon Investment Management Inc. purchased a new stake in Novo Nordisk A/S in the second quarter worth $207,000. Chicago Capital LLC lifted its position in shares of Novo Nordisk A/S by 61.1% during the second quarter. Chicago Capital LLC now owns 10,922 shares of the company’s stock worth $1,559,000 after purchasing an additional 4,144 shares during the last quarter. Finally, Oxbow Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 25.9% during the second quarter. Oxbow Advisors LLC now owns 2,261 shares of the company’s stock valued at $323,000 after purchasing an additional 465 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 3.0 %

NVO stock traded down $2.60 during trading on Monday, reaching $85.05. 6,088,233 shares of the company traded hands, compared to its average volume of 4,615,631. The company has a market capitalization of $381.66 billion, a price-to-earnings ratio of 27.52, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The business has a 50 day simple moving average of $103.06 and a 200 day simple moving average of $121.08. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research analyst reports. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.